Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Cancer Research

• Publication date

  2007-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-2757PMID 17606732
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular biology of neuroblastoma

  2007cited by this paper
• Proteomic analysis of anti‐angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line

  2006cited by this paper
• Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.

  2006cited by this paper
• Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.

  2006cited by this paper
• Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin

  2005cited by this paper
• The role of apoptosis in cancer development and treatment response

  2005cited by this paper
• Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy

  2005cited by this paper
• Caspase-independent cell death

  2005cited by this paper
• Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells

  2004cited by this paper
• Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer

  2004cited by this paper
• Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin.

  2004cited by this paper
• Determinants of Rapamycin Sensitivity in Breast Cancer Cells

  2004cited by this paper
• Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

  2004cited by this paper
• Vinca alkaloids

  2004cited by this paper
• Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN

  2003cited by this paper
• Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.

  2003cited by this paper
• Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.

  2003cited by this paper
• Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma.

  2002cited by this paper
• Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis.

  2002cited by this paper
• In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression

  2002cited by this paper
• Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

  2002cited by this paper
• Inhibition of neuroblastoma-induced angiogenesis by fenretinide.

  2001cited by this paper
• Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

  2001cited by this paper
• 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.

  2000cited by this paper
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

  2000cited by this paper
• The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

  2000cited by this paper
• Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas.

  2000cited by this paper
• Modulation of mitogen-activated protein kinases and phosphorylation of Bcl-2 by vinblastine represent persistent forms of normal fluctuations at G2-M1.

  2000cited by this paper
• The anaphase-promoting complex: new subunits and regulators.

  1999cited by this paper
• Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma.

  1999cited by this paper
• Antiangiogenesis is produced by nontoxic doses of vinblastine.

  1999cited by this paper
• Molecular biology of neuroblastoma.

  1999cited by this paper
• Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.

  1998cited by this paper
• Human neuroblastoma cells produce extracellular matrix‐degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo

  1998cited by this paper
• Microtubules and actin filaments: dynamic targets for cancer chemotherapy.

  1998cited by this paper
• New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay.

  1997cited by this paper
• A metastatic neuroblastoma model in SCID mice

  1996cited by this paper
• Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer.

  1996cited by this paper
• Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma.

  1996cited by this paper
• Mechanism of action of the immunosuppressant rapamycin.

  1995cited by this paper
• Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation.

  1995cited by this paper
• Rapamycin: A novel immunosuppressive macrolide

  1994cited by this paper
• Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.

  1993cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment.

  1993cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

  1993cited by this paper
• Differentiation‐related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants

  1992cited by this paper
• Portal Hypertension: Clinical and Physiological Aspects

  1992cited by this paper
• A New Human Highly Tumorigenic Neuroblastoma Cell Line with Undetectable Expression of N-myc

  1990cited by this paper
• [Transplacental gas exchange].

  1988cited by this paper
• Vinca alkaloids.

  1988cited by this paper
• Vascular toxicity associated with antineoplastic agents.

  1986cited by this paper
• Cisplatin, vinblastine, and bleomycin (CVB) therapy for relapsed disseminated neuroblastoma.

  1984cited by this paper
• New antitumor substances of natural origin.

  1981cited by this paper
• Inhibition of the immune response by rapamycin, a new antifungal antibiotic.

  1977cited by this paper
• Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture.

  1973cited by this paper

• The chick embryo chorioallantoic membrane patient-derived xenograft (PDX) model.

  2023cites this paper
• Technical Implications of the Chicken Embryo Chorioallantoic Membrane Assay to Elucidate Neuroblastoma Biology

  2023cites this paper
• Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma

  2023cites this paper
• CAM Model: Intriguing Natural Bioreactor for Sustainable Research and Reliable/Versatile Testing

  2023cites this paper
• Effects of Monensin and Rapamycin Combination Therapy on Tumor Growth and Apoptosis in a Xenograft Mouse Model of Neuroblastoma

  2023cites this paper
• New Visions on Natural Products and Cancer Therapy: Autophagy and Related Regulatory Pathways

  2022cites this paper
• Optimization and Pharmacokinetic Evaluation of Synergistic Fenbendazole and Rapamycin Co-Encapsulated in Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles

  2021cites this paper
• Advances in pharmacotherapy for neuroblastoma

  2021cites this paper
• Characterization of Anti-Angiogenic Chemo-Sensitization via Longitudinal Ultrasound Localization Microscopy in Colorectal Carcinoma Tumor Xenografts

  2021cites this paper
• Ganglioneuroblastoma Found on an Infant with Langerhans Cell Histiocytosis after Several Months of Chemotherapy: A Case Report

  2020cites this paper
• The CAM Assay as an Alternative In Vivo Model for Drug Testing.

  2020cites this paper
• Pre-application of arsenic trioxide may potentiate cytotoxic effects of vinorelbine/docetaxel on neuroblastoma SK-N-SH cells.

  2019cites this paper
• The effects of anticancer medicinal herbs on vascular endothelial growth factor based on pharmacological aspects: a review study

  2019cites this paper
• Targeting Angiogenesis in Neuroblastoma

  2019cites this paper
• Antiangiogenic Effects of Coumarins against Cancer: From Chemistry to Medicine

  2019cites this paper
• Role of GOLPH3 and TPX2 in Neuroblastoma DNA Damage Response and Cell Resistance to Chemotherapy

  2019cites this paper
• The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research.

  2018cites this paper
• mTORC1 drives HIF-1  and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3

  2018cites this paper
• Evaluation of essential oils from 22 Guatemalan medicinal plants for in vitro activity against cancer and established cell lines

  2018influential citation
• The chick embryo chorioallantoic membrane as an in vivo experimental model to study human neuroblastoma

  2018cites this paper
• Phytocompounds Targeting Cancer Angiogenesis Using the Chorioallantoic Membrane Assay

  2017cites this paper
• Didymin: an orally active citrus flavonoid for targeting neuroblastoma

  2017cites this paper
• Investigational drugs in phase II clinical trials for the treatment of neuroblastoma

  2017cites this paper
• A polyphenol complex from Thymus vulgaris L. plants cultivated in the Campania Region (Italy): New perspectives against neuroblastoma

  2016cites this paper
• Therapeutic Strategies, the Concept of “Normalization” and the Role of VEGF Inhibition

  2016cites this paper
• Combination of cytotoxic agents and targeted therapy for the treatment of advanced sarcomas: preclinical background and early clinical development

  2016cites this paper
• The Role of Microenvironment in the Control of Tumor Angiogenesis

  2016cites this paper
• Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer

  2016cites this paper
• New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK

  2015influential citation
• Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.

  2015cites this paper
• Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models.

  2015cites this paper
• Influence Evaluation of Ocimum Sanctum Leaf Extract on Angiogenesis by using Chick Chorioallantoic Membrane (CAM) Assay

  2015cites this paper
• mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3

  2014cites this paper
• Exploiting intrinsic nanoparticle toxicity: the pros and cons of nanoparticle-induced autophagy in biomedical research.

  2014cites this paper
• Combined Therapeutic Effects of Vinblastine and Astragalus Saponins in Human Colon Cancer Cells and Tumor Xenograft via Inhibition of Tumor Growth and Proangiogenic Factors

  2014cites this paper
• Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors

  2014influential citation
• The chick embryo chorioallantoic membrane as a model for tumor biology.

  2014cites this paper
• Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.

  2013cites this paper
• Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models.

  2013cites this paper
• AKT Kinase Pathway: A Leading Target in Cancer Research

  2013cites this paper
• Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma

  2013cites this paper
• Role of PI3K Inhibitors in Sensitizing Neuroblastoma Cells to Apoptosis

  2013cites this paper
• Anti-angiogenesis in neuroblastoma.

  2013cites this paper
• Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

  2012cites this paper
• Inflammation and antiangiogenesis in cancer.

  2012cites this paper
• 11 The Different Faces of Angiogenesis in Neuroblastoma

  2012cites this paper
• Combining Doublecortin-Like Kinase Silencing and Vinca Alkaloids Results in a Synergistic Apoptotic Effect in Neuroblastoma Cells

  2012cites this paper
• The Different Faces of Angiogenesis in Neuroblastoma

  2012cites this paper
• . 1 Neuroblastoma and doublecortin-like kinase 1 . 1 . 1 Neuroblastoma

  2012cites this paper
• Didymin Induces Apoptosis by Inhibiting N-Myc and Upregulating RKIP in Neuroblastoma

  2011cites this paper
• Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

  2011cites this paper
• Short interfering RNA directed against Slug blocks tumor growth, metastasis formation, and vascular leakage in bladder cancer

  2011cites this paper
• Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma

  2011cites this paper
• Comparative pathological and cytogenetical study of ethanolic extract of Vinca rosea L. and Vinblastine in treating mammary gland adenocarcinoma implanted mice

  2011cites this paper
• Targeting Angiogenesis for Controlling Neuroblastoma

  2011cites this paper
• Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture

  2011cites this paper
• The Proteasome Inhibitor Bortezomib Enhances ATRA-Induced Differentiation of Neuroblastoma Cells via the JNK Mitogen-Activated Protein Kinase Pathway

  2011cites this paper
• Aufnahme und Metabolismus von 6-Fluoro-DOPA und 6-Fluoro-Dopamin in Neuroblastomzellen und

  2010cites this paper
• p53 family: Therapeutic targets in neuroblastoma.

  2010cites this paper
• Targeting multiple angiogenic pathways for the treatment of neuroblastoma.

  2010cites this paper
• Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens

  2010cites this paper
• Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.

  2010cites this paper
• Pharmacotherapy of neuroblastoma

  2010cites this paper
• The Chick Embryo Chorioallantoic Membrane in the Study of Angiogenesis and Metastasis: The CAM assay in the study of angiogenesis and metastasis

  2010cites this paper
• The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.

  2009cites this paper
• New therapeutic targets for the treatment of high‐risk neuroblastoma

  2009influential citation
• Novel experimental targeted therapy of neuroblastoma

  2009cites this paper
• Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine.

  2009cites this paper
• The Combined Therapeutic Effects of Bortezomib and Fenretinide on Neuroblastoma Cells Involve Endoplasmic Reticulum Stress Response

  2009cites this paper
• Cancer microenvironment and therapeutic implications

  2009cites this paper
• New Indications for Established Drugs Able to Modify Tumour-Host Interactions

  2009cites this paper
• Combined Bcl-2/Mammalian Target of Rapamycin Inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Non–Small Cell Lung Tumor Xenograft Model

  2009cites this paper
• Antitumorale und antiangiogenetische Effekte von Biomodulatoren beim malignen Melanom und Angiosarkom

  2008cites this paper
• Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity

  2008cites this paper
• Molecular targets and targeted therapies for malignant mesothelioma.

  2008cites this paper
• PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma.

  2008cites this paper
• The chick embryo chorioallantoic membrane in the study of tumor angiogenesis.

  2008cites this paper
• Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.

  2008cites this paper
• Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin

  2008cites this paper
• mTOR pathway and mTOR inhibitors as agents for cancer therapy.

  2008cites this paper
• Chick embryo chorioallantoic membrane as a useful tool to study angiogenesis.

  2008cites this paper
• Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

  2008cites this paper
• Doublecortin-like kinase: a potential therapeutic target for neuroblastoma

  2007cites this paper